ArticleCureus2026
Skin Deep: A Case Report of Erythema Nodosum Induced by Dupilumab Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dupilumab is a fully human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, thereby attenuating type 2 inflammatory pathways. It is currently approved for the treatment of severe eosinophilic asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other allergic conditions. Erythema nodosum (EN) is the most common form of panniculitis, characterized by tender, erythematous subcutaneous nodules typically distributed over the extensor surfaces of the lower extremities. Drug-induced EN represents a minority of all EN cases and has been rarely described in association with biologic therapies including anti-IL-4/13 and anti-IL-5 agents. Notably, dupilumab-associated EN is exceedingly rare, and this report describes a case of clinically suspected dupilumab-associated EN occurring in a patient with severe eosinophilic asthma in the setting of suppressed peripheral blood eosinophils following a treatment interruption. We present the case of a 68-year-old woman with severe eosinophilic asthma who developed clinically suspected EN shortly after initiation of dupilumab therapy and a subsequent two-month treatment interruption. She presented with painful bilateral lower extremity and upper arm nodules following her fifth injection. Notably, her peripheral blood eosinophil count, which had been persistently elevated for more than one year before dupilumab initiation, transiently rebounded during the treatment gap but was adequately suppressed (0.2 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.